- Home
- NUS vs ABSI Comparison
NUS vs ABSI Comparison
Compare NUS & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUS | ABSI |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | 8600 | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.1M | 997.8M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NUS | ABSI |
|---|---|---|
| Price | $4.85 | $8.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.96 |
| AVG Volume (30 Days) | 468.8K | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,176,718,000.00 | $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | $7.14 | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $4.49 | $2.24 |
| 52 Week High | $14.62 | $12.06 |
Technical Indicators
Market Signals| Indicator | NUS | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 40.77 |
| Support Level | $4.52 | $6.69 |
| Resistance Level | $4.95 | $10.03 |
| Average True Range (ATR) | 0.18 | 0.54 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 67.09 | 0.81 |
Price Performance
Historical ComparisonAbout NUS Nu Skin Enterprises Inc.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.